Search
Turkey tutorial focused on lymphoma
The 8th EHA-TSH Hematology Tutorial was held on April 6-7, 2019 in Izmir, Turkey. This marks yet another pleasant and fruitful collaboration between EHA and the Turkish Society of Hematology.
Read moreNew data exchange platform on rare diseases
The European Commission (EC) launched a new online knowledge-sharing platform – the European Platform on Rare Disease Registration (EU RD Platform) – on February 28, 2019.
Read more“Science is all about synergy” - Francesca Vinchi, woman in hematology/EHA volunteer
This Women’s History Month, we are putting the spotlight on women in hematology. One of them is Francesca Vinchi, also an EHA Volunteer.
Read moreMeet Antonio Almeida, our February Volunteer of the Month
EHA is a Public Benefit Organization under Dutch law.
Read moreMeet Antonio Almeida, our February Volunteer of the Month
EHA is a Public Benefit Organization under Dutch law.
Read moreUptake of CAR T cell therapy in Europe
Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.
Read moreMichel Boiron 1925-2018
It is with great sadness that we announce the passing of Professor Michel Boiron last December 3. Boiron was the founding President (1992-1994) of the European Hematology Association (EHA).
Read moreEHA and Polish Society’s third tutorial together focused on myeloid and lymphoid leukemias
Seventy-five participants from Europe and the Middle East learned about the advances in biology, genetic characteristics, diagnostic approaches and therapy of leukemias during the EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias in Warsaw, Poland.
Read moreStopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Read more